Benevity Releases First Enterprise Impact Platform to Solve CSR and Social Impact's Biggest Challenges
CALGARY, Alberta, May 16, 2025 (GLOBE NEWSWIRE) —
Benevity Inc.
today released its next-generation Enterprise Impact Platform, delivering the first all-in-one solution to simplify and scale corporate social responsibility (CSR) and social impact programs. The platform unifies giving, volunteering, grants management, and employee mobilization—empowering companies to better connect purpose with measurable business results.
Trusted by a community of more than 900 clients worldwide, Benevity developed the
Enterprise Impact Platform
to address the most pressing challenges faced by CSR and social impact professionals today: disconnected systems, limited visibility, employee disengagement, and risk exposure.
Benevity's secure, enterprise-grade solution meets those needs head-on, offering unmatched governance, global reach, and the world's largest fully vetted nonprofit network. The platform allows organizations to scale social impact and enhance the way they engage with communities, attract and retain talent, improve brand reputation, and foster innovation throughout the enterprise.
'Connecting purpose to business goals for leaders who are focused on creating performing and enduring organizations is our top priority,' said Chris Maloof, Chief Executive Officer, Benevity. 'As CSR leaders strive to keep up with increasing responsibilities and a changing environment, our Enterprise Impact Platform is purpose-built to help drive scalable, measurable, and transformative impact programs from a single, unified environment.'
The recently released 2025 Benevity
State of Corporate Purpose Report
noted that the corporate purpose landscape is in a state of significant flux, with nearly two-thirds of businesses redefining their purpose strategy in the past year amid growing cross-functional demands on CSR leaders.
Grounded in client-centric design, Benevity's Enterprise Impact platform leverages industry-leading, AI-enabled design to provide a more complete view of purpose programs and improved visibility into engagement and impact metrics.
Benevity's Enterprise Impact Platform Delivers:
Real Impact, Real Results
Some of the world's leading organizations have successfully implemented Benevity's Enterprise Impact Platform to drive measurable social and business impact within their organizations, in their communities, and society at large.
As a part of its commitment to helping people achieve brighter financial futures, Discover continues to make a meaningful impact in communities across the country. The company's volunteer program, focused on education and community support, empowers employees to give back in ways that matter most to them. In addition, the 'You Care We Share' program, enabled by Benevity, has seamlessly integrated donation matching, volunteer rewards, and hybrid volunteering into one cohesive platform.
Discover's community-related results include:
Adobe's Global Employee Community Fund (ECF) uses Benevity's Enterprise Impact Platform to power its global giving, including $30M+ to local communities. Adobe's ECF empowers employees to nominate and select nonprofits for $20K grants. The program is localized, employee-led, and streamlined to reduce nonprofit burden.
Adobe's global giving highlights include:
The Future of Purpose is Enterprise-Ready
The same
State of Corporate Purpose Report
reflects that executives are committed to investing in social impact programs because it's good for business (92%) and
prior Benevity research shows
that 76% of CSR leaders reported plans to increase investments. The desire to do more good and power purpose at work is coupled with growing expectations for accountability, efficiency, and employee engagement. The Benevity Enterprise Impact Platform is uniquely designed to meet the moment.
About Benevity
Benevity
, a certified B Corporation, is the leading global provider of social impact software, providing the only integrated suite of community investment and employee, customer and nonprofit engagement solutions. Recognized as one of Fortune's Impact 20, Benevity provides a robust, all-in-one SaaS platform designed to simplify and scale CSR and social impact programs. The platform unifies giving, volunteering, grants management, and employee mobilization - empowering companies to connect purpose with measurable business results. With software that is available in 22 languages, Benevity has processed more than $18.5 billion in donations and 99 million hours of volunteering time to support 513,000 nonprofits worldwide. The company's solutions have also facilitated 1.5 million micro-actions and managed grants worth $18 billion. For more information, visit
benevity.com
.
Media Contact:
Indrani Ray-Ghosal │ Press & Analyst Relations │ 1.647.574.9559 │
press@benevity.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 'Company,' 'we,' 'us,' or 'our') within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Without limiting the foregoing, we may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'forecast,' 'guidance,' 'outlook,' 'may,' 'can,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ('FDA') approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ('EMA') approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS InvestorsIR@ ext. 150 MediaPR@ 650-260-7120 ext. 150Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
ONAR Appoints Esteemed Executive Howard Palefsky to the Company's Board of Directors
Miami, FL, June 10, 2025 (GLOBE NEWSWIRE) -- Onar Holding Corporation (OTCQB: ONAR), a leading marketing technology company and network of marketing agencies, today announced the appointment of Howard Palefsky to ONAR's Board of Directors. Palefsky, an esteemed CEO, VC & PE partner, entrepreneur, board member, chair, and investor with experience across the life sciences, healthcare, and medical technology industries, will also chair the Company's Governance and Nominating Committee. 'It is an honor to welcome Howard to our Board of Directors and as Chair of our Governance and Nominating Committee,' stated Claude Zdanow, CEO of ONAR. 'Howard's extensive expertise with financial markets and public companies, coupled with his experience in healthcare, will be invaluable to our company's growth and further expansion in the healthcare marketing sector." 'ONAR has gone through significant transformations within the last year and is seeing accelerated growth within the middle-market,' stated Palefsky. 'I look forward to helping the Company on its current trajectory and sharing my past experiences to help fuel its success.' Palefsky has led life-science and medical technology organizations to achieve significant growth, creating value exceeding $4B. He has also sat on the boards of more than 30 organizations, including Target Therapeutics, which was acquired by Boston Scientific, Pulmonx, and M8 Pharmaceuticals, which was acquired by Acino. Palefsky has played a pivotal role in establishing more than 20 businesses, spearheading innumerous capital raises, Initial Public Offerings, and acquisitions. Additionally, he has overseen more than 40 new product launches across the U.S., Europe, LATAM, and Asia Pacific, gaining invaluable strategic insight into regulatory affairs and reimbursement mechanics in multiple geographies. ONAR is focused on building out its Board of Directors, having also recently announced the appointment of renowned marketing executive Jon Bond to its board. These two appointments are expected to enhance the Company's business operations across multiple domains, including merger and acquisition strategy, growth initiatives, and agency network advancement. About ONARONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network. The Company's mission is to power unparalleled marketing services that drive revenue growth through an integrated, AI-driven approach. Committed to honor, candor, and best-in-class results, ONAR's agency network offers a range of services including performance marketing & SEO, healthcare marketing, and experiential marketing & events. ONAR's agencies focus on servicing middle-market and growth stage companies, and the Company is actively searching for agencies to acquire and become part of the network. Additionally, the Company's technology incubator, ONAR Labs, is focused on identifying, developing, and commercializing innovative marketing technology solutions. For more information, visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Media Contact:Sara ScullyMarketing ManagerONAR213-437-3081IR@
Yahoo
24 minutes ago
- Yahoo
MACOM IMS 2025 Product Preview
LOWELL, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Inc. ('MACOM'), a leading supplier of semiconductor products, today announced availability of a wideband front end module (FEM) covering 2 to 18 GHz. Ideal for electronic countermeasures (ECM) and phased array radar applications, the miniature multi-chip ENGSD00088 Transmit/Receive Module integrates a high power 3-stage Gallium Nitride (GaN) Power Amplifier (PA), a 3-stage Gallium Arsenide (GaAs) Low Noise Amplifier (LNA) and a transmit/receive (T/R) switch with a fail-safe antenna termination, all within a compact package. The transmit path delivers 2.5 W typical saturated output power with power added efficiency (PAE) of 24%, along with 25 dB of large signal gain. The receive side provides 27 dB of gain with a low noise figure of 3.5 dB and 26 dBm output third order intercept point (OIP3). The receive channel can handle input powers up to +20 dBm with an option to add a limiter for additional protection input power handling. Ideally suited for wideband phased array architectures, the ENGSD00088 offers high gain in both transmit and receive modes, minimizes board space and simplifies system design, while its high performance allows mission-critical reliability. The FEM will be on display at MACOM's Booth 943 at the upcoming International Microwave Symposium (IMS) in San Francisco, CA from June 17 to 19, 2025. Additionally, information and sample requests are available here. About MACOMMACOM designs and manufactures high-performance semiconductor products for the Telecommunications, Industrial and Defense, and Data Center industries. MACOM services over 6,000 customers annually with a broad product portfolio that incorporates RF, Microwave, Analog and Mixed Signal and Optical semiconductor technologies. MACOM has achieved certification to the IATF16949 automotive standard, the AS9100D aerospace standard, the ISO9001 international quality standard and the ISO14001 environmental management standard. MACOM operates facilities across the United States, Europe, Asia and is headquartered in Lowell, Massachusetts. To learn more, visit Company Contact:MACOM Technology Solutions FerrantiVice President, Corporate Development and Investor RelationsP: 978-656-2977E:
